Carbonyl Reduction of Timiperone in Human Liver Cytosol

    loading  Checking for direct PDF access through Ovid



This in vitro study using human liver enzymes was undertaken in order to compare the mechanism of metabolic reduction of timiperone, a potent butyrophenone neuroleptic, with that of haloperidol. Conversion of timiperone to reduced timiperone in liver cytosol was confirmed. The carbonyl reductase inhibitors (menadione IC50 5-18 μM; ethacrynic acid IC50 26-51 μM) potently inhibited both timiperone reductase and haloperidol reductase activity, while 4-methylpyrazole (alcohol dehydrogenase inhibitor) had no effect and phenobarbital (aldehyde reductase inhibitor) had a weak inhibitory effect. The formation of reduced timiperone was highly correlated with the formation of reduced haloperidol(r=0.87, n=6, P<0.02). Timiperone reductase activity was approximately 40% lower than haloperidol reductase activity (at a substrate concentration of 100 μM, two-tailed t-test, P<0.05). The Michaelis-Menten constant (Km) and maximum velocity (Vmax) of reduced timiperone formation were much lower than reduced haloperidol formation (Km values: 29.7±15.1 versus 381.3±1.1 μM, n=3, P<0.01; Vmax: 0.81±0.19 versus 6.00±1.47 nmol/mg/min; n=3, P<0.05). However, the ratio Vmax/Km (clearance) for timiperone was 1.3-2.4 times higher than for haloperidol, indicating that metabolic clearance of timiperone by carbonyl reductase may be similar to or slightly higher than for haloperidol.

Related Topics

    loading  Loading Related Articles